Output

European Child & Adolescent Psychopharmacology Network

Clinical trials

References 
(publications with at least two authors members of the network).

2016

  1. Inglis SK, Carucci S, Garas P, Häge A, Banaschewski T, Buitelaar JK, Dittmann RW, Falissard B, Hollis C, Kovshoff H, Liddle E, McCarthy S, Nagy P, Neubert A, Rosenthal E, Sonuga-Barke E, Wong I, Zuddas A, Coghill D; ADDUCE Consortium. Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. BMJ Open. 2016 Apr 26;6(4):e010433. doi: 10.1136/bmjopen-2015-010433.
  2. Kovshoff H, Banaschewski T, Buitelaar JK, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Falissard B, Grimshaw DG, Hollis C, Inglis S, Konrad K, Liddle E, McCarthy S, Nagy P, Thompson M, Wong IC, Zuddas A, Sonuga-Barke EJ. Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. J Child Adolesc Psychopharmacol. 2016 Mar 23. [Epub ahead of print]
  3. Gassó P, Sánchez-Gistau V, Mas S, Sugranyes G, Rodríguez N, Boloc D, de la Serna E, Romero S, MorenoD, MorenoC, Díaz-Caneja CM, Lafuente A, Castro-Fornieles J (2016). Association of CACNA1C and SYNE1 in offspring of patients with psychiatric disorders. Psychiatry Research (available online 2 september 2016).  http://dx.doi.otg/10.1016/j.psychres.2016.08.058
  4. Pina-Camacho L, Del Rey-Mejías Á, Janssen J, Bioque M, González-Pinto A, Arango C, Lobo A, Sarró S, Desco M, Sanjuan J, Lacalle-Aurioles M, Cuesta MJ, Saiz-Ruiz J, Bernardo M, Parellada M; PEPs Group Collaborators: Cabrera B, Bargalló N, Moreno C, Alemán-Gómez Y, Fernández M, González I, Fayed N, Barcones MF, Aguilar EJ, Garcia-Marti G, Bulbena A, Bergé D, Vieta E, Torrent C, Castro-Fornieles J, Baeza I, Contreras F, Albacete A, Bobes J, García-Portilla MP, Rodriguez-Jimenez R, Morales-Muñoz I, Usall J, Butjosa A, Landin-Romero R, Pomarol-Clotet E (2016). Age at first-episode modulates diagnosis-related structural brain abnormalities in psychosis. Schizophrenia Bulletin 42(2):344-57.

2015

  1. Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, Moreno C, Vitiello B, Vorstman J, Zuddas A & European Child Adolescent Clinical Psychopharmacology Network. Eur Neuropsychopharmacol. 2015; 25:1513-31.
  2. Parellada M, Castro-Fornieles J, Gonzalez-Pinto A, Pina-Camacho L, Moreno D, Rapado-Castro M, Otero S, del Serna E, Moreno C, Baeza I, Graell M, Arango C (2015). Predictors of Functional and Clinical Outcome in Early-Onset First-Episode Psychosis. The Journal of Clinical Psychiatry. 76(11):e1441-8, 2015.
  3. Sanchez-Gistau V, Romero S, Moreno D, de la Serna E, Baeza I, Sugranyes G, Moreno C, Sanchez-Gutierrez T, Rodriguez-Toscano E, Castro-Fornieles J (2015). Psychiatric disorders in child and adolescent offspring of patients with schizophrenia and bipolar disorder: a controlled study. Schizophrenia Research, 168(1-2):197-203, 2015. (F.I.: 3.923).
  4. Garcia-Amador M, Merchán-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J, Baeza I, de la Serna E, Alda JA, Muñoz D, Andrés-Nestares P, Martínez-Cantarero, Arango C (2015). Neurological side-effects of antipsychotics in children and adolescents. Journal of Clinical Psychopharmacology 35(6):686-93.
  5. Rapado-Castro M, Bartholomeusz CF, Castro-Fornieles J, González-Pinto A, Otero S, Baeza I, Moreno C, Graell M, Janssen J, Bargalló N, Pantelis C, Desco M, Arango C (2015).  Gender effects on brain changes in early-onset psychosis. Eur Child Adolesc Psychiatry, European Child and Adolescent Psychiatry, 24(10):1193-20, 2015.
  6. Sanchez-Gistau V, Baeza I, Arango C, González-Pinto A, de la Serna E, Parellada M, Graell M, Paya B, Llorente C, Castro-Fornieles J. The affective dimension of early-onset psychosis and its relationship with suicide. J Child Psychol Psychiatry. J Child Psychol Psychiatry. 2015 Jul;56(7):747-55. doi: 10.1111/jcpp.12332.
  7. Pina-Camacho L, Garcia-Prieto J, Parellada M, Castro-Fornieles J, Gonzalez-Pinto AM, Bombin I, Graell M, Paya B, Rapado-Castro M, Janssen J, Baeza I, Pozo FD, Desco M, Arango C. Predictors of schizophrenia spectrum disorders in early-onset first episodes of psychosis: a support vector machine model. Eur Child Adolesc Psychiatry. 2015 Apr;24(4):427-40.

2014

  1. Banaschewski T, Johnson M, Lecendreux M, Zuddas A, Adeyi B, Hodgkins P, Squires LA, Coghill DR. Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2014; 28: 1191-203
  2. Arango C, Giráldez M, Merchán-Naranjo , Baeza I, Castro-Fornieles J, Alda JA, Martinez-Cantarero C, Moreno C, de Andrés P, Cuerda C, de la Serna E, Correll CU, Fraguas D, Parellada M (2014)   J. Second-Generation Antipsychotics in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. Journal of the American Academy of Child & Adolescent Psychiatry 53(11): 1179-90.
  3. Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, Civil R, Dauphin M, Higgins N, Lyne A, Gasior M, Squires LA. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014, 53: 647-657.
  4. Coghill DR, Banaschewski T, Lecendreux M, Zuddas A, Dittmann RW, Otero IH, Civil R, Bloomfield R, Squires LA. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. Eur Child Adolesc Psychiatry. 2014, 23:61-8.
  5. Janssen J, Alemán-Gómez Y, Schnack H, Balaban E, Pina-Camacho L, Alfaro-Almagro F, Castro-Fornieles J, Otero S, Baeza I, Moreno C, Bargalló N, Parellada M, Arango C, Desco M. Cortical morphology of adolescents with bipolar disorder and with schizophrenia. Schizophr Res. 2014, 158:91-9.
  6. Fraguas D, Merchán-Naranjo J, del Rey-Mejías Á, Castro-Fornieles J, González-Pinto A, Rapado-Castro M, Pina-Camacho L, Díaz-Caneja CM, Graell M, Otero S, Baeza I, Moreno C, Martínez-Cengotitabengoa M, Rodríguez-Toscano E, Arango C, Parellada M. A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis. Schizophr Res. 2014, 158: 126-33
  7. Martínez-Cengotitabengoa M, Micó JA, Arango C, Castro-Fornieles J, Graell M, Payá B, Leza JC, Zorrilla I, Parellada M, López MP, Baeza I, Moreno C, Rapado-Castro M, González-Pinto A. Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study. Schizophr Res. 2014, 156: 23-9.
  8. Fraguas D, Del Rey-Mejías A, Moreno C, Castro-Fornieles J, Graell M, Otero S, Gonzalez-Pinto A, Moreno C, Baeza I, Martínez-Cengotitabengoa M, Arango C, Parellada M. Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: a 2-year longitudinal study. Schizophr Res. 2014, 152:130-8
  9. Thissen AJ, Luman M, Hartman C, Hoekstra P, van Lieshout M, Franke B, Oosterlaan J, Rommelse NN, Buitelaar JK. Attention-deficit/hyperactivity disorder (ADHD) and motor timing in adolescents and their parents: familial characteristics of reaction time variability vary with age. J Am Acad Child Adolesc Psychiatry. 2014, 53:1010-1019.
  10. Groenman AP, Oosterlaan J, Greven CU, Vuijk PJ, Rommelse N, Franke B, Hartman CA, Hoekstra PJ, Sergeant J, Faraone SV, Buitelaar J. Neurocognitive predictors of substance use disorders and nicotine dependence in ADHD probands, their unaffected siblings, and controls: a 4-year prospective follow-up. J Child Psychol Psychiatry. 2014 [Aug 19; Epub ahead of print]
  11. van Ewijk H, Heslenfeld DJ, Zwiers MP, Faraone SV, Luman M, Hartman CA, Hoekstra PJ, Franke B, Buitelaar JK, Oosterlaan J. Different mechanisms of white matter abnormalities in attention-deficit/hyperactivity disorder: a diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry. 2014, 53:790-9.
  12. Richards JS, Hartman CA, Franke B, Hoekstra PJ, Heslenfeld DJ, Oosterlaan J, Arias Vásquez A, Buitelaar JK. Differential susceptibility to maternal expressed emotion in children with ADHD and their siblings? Investigating plasticity genes, prosocial and antisocial behaviour. Eur Child Adolesc Psychiatry. 2014 [Jun 15. Epub ahead of print].
  13. Vorstman JA, Spooren W, Persico AM, Collier DA, Aigner S, Jagasia R, Glennon JC, Buitelaar JK. Using genetic findings in autism for the development of new pharmaceutical compounds. Psychopharmacology (Berl). 2014, 231:1063-78.
  14. Glennon J, Purper-Ouakil D, Bakker M, Zuddas A, Hoekstra P, Schulze U, Castro-Fornieles J, Santosh PJ, Arango C, Kölch M, Coghill D, Flamarique I, Penzol MJ, Wan M, Murray M, Wong IC, Danckaerts M, Bonnot O, Falissard B, Masi G, Fegert JM, Vicari S, Carucci S, Dittmann RW, Buitelaar JK; The PERS Consortium. Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur Child Adolesc Psychiatry. 2013 [Dec 15; Epub ahead of print] 

2013

  1. Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry. 2013, 13:237
  2. Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, Adeyi B, Squires LA, Coghill D. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013, 27:829-40.
  3. Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs. 2013, 27:743-51.
  4. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013, 23:1208-18.
  5. Bralten J, Franke B, Waldman I, Rommelse N, Hartman C, Asherson P, Banaschewski T, Ebstein RP, Gill M, Miranda A, Oades RD, Roeyers H, Rothenberger A, Sergeant JA, Oosterlaan J, Sonuga-Barke E, Steinhausen HC, Faraone SV, Buitelaar JK, Arias-Vásquez A. Candidate genetic pathways for attention-deficit/hyperactivity disorder (ADHD) show association to hyperactive/impulsive symptoms in children with ADHD. J Am Acad Child Adolesc. Psychiatry. 2013, 52:1204-1212.
  6. Payá B, Rodríguez-Sánchez JM, Otero S, Muñoz P, Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, Soutullo C, Baeza I, Rapado-Castro M, Sáenz-Herrero M, Moreno C, Arango C. Premorbid impairments in early-onset psychosis: differences between patients with schizophrenia and bipolar disorder. Schizophr Res. 2013, 146:103-10.
  7. van der Meer JM, Harfterkamp M, van de Loo-Neus G, Althaus M, de Ruiter SW, Donders AR, de Sonneville LM, Buitelaar JK, Hoekstra PJ, Rommelse NN. A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms. J Clin Psychopharmacol. 2013; 33:824-7
  8. Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell,  […] Banaschewski T, […],  Buitelaar JK, [….], Wray NR. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013, 45:984-94.
  9. Groenman AP, Oosterlaan J, Rommelse NN, Franke B, Greven CU, Hoekstra PJ, Hartman CA, Luman M, Roeyers H, Oades RD, Sergeant JA, Buitelaar JK, Faraone SV. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry. 2013; 203:112-9.

    Mota NR, Bau CH, Banaschewski T, Buitelaar JK, Ebstein RP, Franke B, Gill M, Kuntsi J, Manor I, Miranda A, Mulas F, Oades RD, Roeyers H, Rothenberger A, Sergeant JA, Sonuga-Barke EJ, Steinhausen HC, Faraone SV, Asherson P. Association between DRD2/DRD4 interaction and conduct disorder: a potential developmental pathway to alcohol dependence. Am J Med Genet B Neuropsychiatr Genet. 2013, 162B:546-9.

  10. Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. J Child Adolesc Psychopharmacol. 2013, 23:194-9.
  11. Murray ML, Insuk S, Banaschewski T, Neubert AC, McCarthy S, Buitelaar JK, Coghill D, Dittmann RW, Konrad K, Panei P, Rosenthal E, Sonuga-Barke EJ, Wong IC. An inventory of European data sources for the long-term safety evaluation of methylphenidate. Eur Child Adolesc Psychiatry. 2013, 22: 605-18.
  12. Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Döpfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC, Sergeant J; European ADHD Guidelines Group. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomizedcontrolled trials of dietary and psychological treatments. Am J Psychiatry. 2013, 170: 275-89.
  13. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013, 54: 227-46.
  14. Dietrich A, Ormel J, Buitelaar JK, Verhulst FC, Hoekstra PJ, Hartman CA. Cortisol in the morning and dimensions of anxiety, depression, and aggression in children from a general population and clinic-referred cohort: An integrated analysis. The TRAILS study. Psychoneuroendocrinology. 2013, 38:1281-98.
  15. Noguera A, Ballesta P, Baeza I, Arango C, de la Serna E, González-Pinto A, Parellada M, Graell M, Moreno C, Otero S, Castro-Fornieles J (2013). Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability. J Clin Psychopharmacol 33(4):463-71. 

2012

  1. Banaschewski T, Jennen-Steinmetz C, Brandeis D, Buitelaar JK, Kuntsi J, Poustka L, Sergeant JA, Sonuga-Barke EJ, Frazier-Wood AC, Albrecht B, Chen W, Uebel H, Schlotz W, van der Meere JJ, Gill M, Manor I, Miranda A, Mulas F, Oades RD, Roeyers H, Rothenberger A, Steinhausen HC, Faraone SV, Asherson P. Neuropsychological correlates of emotional lability in children with ADHD. J Child Psychol Psychiatry. 2012, 53:1139-48.
  2. Toplak ME, Sorge GB, Flora DB, Chen W, Banaschewski T, Buitelaar J, Ebstein R, Eisenberg J, Franke B, Gill M, Miranda A, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Sonuga-Barke E, Steinhausen HC, Thompson M, Tannock R, Asherson P, Faraone SV. The hierarchical factor model of ADHD: invariant across age and national groupings? J Child Psychol Psychiatry. 2012; 53:292-303.
  3. Fraguas D, Gonzalez-Pinto A, Micó JA, Reig S, Parellada M, Martínez-Cengotitabengoa M, Castro-Fornieles J, Rapado-Castro M, Baeza I, Janssen J, Desco M, Leza JC, Arango C. Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophr Res. 2012, 137:58-65.
  4. Arango C, Rapado-Castro M, Reig S, Castro-Fornieles J, González-Pinto A, Otero S, Baeza I, Moreno C, Graell M, Janssen J, Parellada M, Moreno D, Bargalló N, Desco M. Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry. 2012, 69:16-26.
  5. Mayoral M, Bombín I, Castro-Fornieles J, González-Pinto A, Otero S, Parellada M, Moreno C, Baeza I, Graell M, Rapado M, Arango C. Longitudinal study of neurological soft signs in first-episode early-onset psychosis. J Child Psychol Psychiatry. 2012, 53:323-31.
  6. Cavanna AE, Rickards H, Worrall R, Hoekstra PJ, Plessen KJ, Roessner V. From ipse dixit to evidence-based guidelines: on the optimal management of Tourette syndrome. Eur J Paediatr Neurol. 2012, 16:310-1.